These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

878 related items for PubMed ID: 19027223

  • 1. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI.
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [Abstract] [Full Text] [Related]

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P.
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [Abstract] [Full Text] [Related]

  • 4. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI.
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [Abstract] [Full Text] [Related]

  • 5. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA.
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

  • 10. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 11. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML.
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [Abstract] [Full Text] [Related]

  • 12. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [Abstract] [Full Text] [Related]

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 14. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
    Ploussard G, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Abbou CC, Vacherot F, de la Taille A.
    BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
    [Abstract] [Full Text] [Related]

  • 15. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N, Saito S, Ishidoya S, Ito A, Saito H, Kato M, Arai Y.
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [Abstract] [Full Text] [Related]

  • 16. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA.
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [Abstract] [Full Text] [Related]

  • 17. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA.
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [Abstract] [Full Text] [Related]

  • 18. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.
    Suardi N, Ficarra V, Willemsen P, De Wil P, Gallina A, De Naeyer G, Schatteman P, Montorsi F, Carpentier P, Mottrie A.
    Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567
    [Abstract] [Full Text] [Related]

  • 19. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [Abstract] [Full Text] [Related]

  • 20. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
    Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.
    BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.